
Marijuana has been and is presently classified as a Schedule I drug under the federal Controlled Substances Act (CSA), defined as having high abuse potential with no accepted medical use (Schedule I also includes heroin, LSD and MDMA (commonly known as “ecstasy”)). First recommended by the Biden Administration in 2023, on December 18, 2025, President Trump signed an Executive Order directing the Department of Justice to “take all necessary steps . . . in the most expeditious manner” to complete the rulemaking process related to rescheduling marijuana to Schedule III of the Controlled Substances Act (CSA). Moving marijuana to Schedule III – defined as drugs with a “moderate to low potential for physical and psychological dependance,” including anabolic steroids and testosterone – would, among other things, acknowledge the widely accepted medical use of marijuana. This in turn could have substantial downstream effects on employers and employees.






